The Lipid Panel Test Strips are intended to measure cholesterol, HDL cholesterol and triglycerides in whole blood on a BioScanner Plus (CardioChek brand) analyzer. The BioScanner Plus (CardioChek brand) analyzer is intended to be used by healthcare professionals to measure blood analytes on a test strip. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipoprotein metabolism disorders. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. Triglycerides measurements are used in the diagnosis and treatment of patients with diabetes mellius, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.

Device Description

The Lipid Panel Test Strips are dry phase test strips that are constructed from a plastic strip holder that holds chemically treated membranes. When whole blood is placed on the test strip, the membranes first separate and isolate the red blood cells, allowing the serum/plasma to flow to the reaction membrane and react to produce a color change. The Lipid Panel Test Strips are for in vitro diagnostic use with the BioScanner Plus (CardioChek brand) reflectance photometer.

AI/ML Overview

Here's a breakdown of the acceptance criteria and study information based on the provided text, using the requested formatting:

1. Table of Acceptance Criteria and Reported Device Performance

Performance Metric	Acceptance Criteria	Reported Device Performance
Precision (Lot Homogeneity)	10% CV	Improved (beyond original 15% CV)

2. Sample Size Used for the Test Set and Data Provenance

The document does not explicitly state the sample size used for the test set or the data provenance (e.g., country of origin, retrospective/prospective). It mentions "scale-up of the process to manufacture larger lots of the test strips" and "increase in manufacturing experience," which led to improved precision. However, specific details about the data collected for this precision study are not provided.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

Not applicable. This device is an in vitro diagnostic (IVD) test strip that measures analytes directly. Ground truth would typically be established through reference laboratory methods rather than expert consensus on images or clinical assessments. The document does not mention the use of experts for establishing ground truth.

4. Adjudication Method for the Test Set

Not applicable. As noted above, ground truth for IVD devices is typically established through a reference method, not expert adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, an MRMC comparative effectiveness study was not done. This device is an in vitro diagnostic (IVD) test strip and not an AI-assisted diagnostic tool that would typically involve human readers.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, if we interpret "standalone" as the performance of the device itself (the test strip and analyzer) without human interpretive input for the measurement. The study focuses on the "precision performance" of the test strips, which is an intrinsic characteristic of the device.

7. The Type of Ground Truth Used

The type of "ground truth" used would be the actual concentrations of cholesterol, HDL cholesterol, and triglycerides in the whole blood samples, as determined by a reference method (though the specific reference method is not stated, it is implied for an IVD device measuring these analytes). The study measured the precision of the device against these true values.

8. The Sample Size for the Training Set

Not applicable. This device is a dry phase test strip that relies on chemical reactions for measurement, not a machine learning algorithm that requires a training set. The "improvements" noted are due to manufacturing processes.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no training set for this type of device.

Summary

{0}------------------------------------------------

SEP 2 4 2002

510(k) SUMMARY

CO22898 This summary of safety and effectiveness information is submitted in compliance with 21CFR807.92.

1. Application Date:
  August 29, 2002

2. Applicant Information:

Polymer Technology Systems, Inc. 7736 Zionsville Road Indianapolis. IN 46268 Contact Person: Margo Enright Phone Number: 317-870-5610 FAX Number: 317-870-5608 e-mail: mme(@diabetes-testing.com

1. Trade Names:
  PTS PANELS Lipid Panel Test Strips

4. Description:

5. Classification Names:

Cholesterol test system Lipoprotein test system Panel: Clinical Chemistry 75 Product Codes: CHH, LBR, JGY

6. Facility Address:

7736 Zionsville Road Indianapolis, IN 46268

Device Classification: 7.

Class I (Regulation: 21 CFR 862.1475, 862.1175, 862.1705)

8. Intended Use:

The Lipid Panel Test Strips are intended to measure cholesterol, HDL cholesterol and triglycerides in whole blood on a BioScanner Plus (CardioChek brand) analyzer. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. Triglycerides measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases

involving lipid metabolism, or various endocrine disorders.

{1}------------------------------------------------

Reason for 510(k): 9.
Device Modification

10. Predicate Device Information

The predicate devices for determination of substantial equivalence is: Name: PTS PANELS Lipid Panel Test Strips Device Company: Polymer Technology Systems. 510(k) Number: K013173

Similarities and Differences between the Lipid Panel Test Strip as presented in the original Special 510(k) and the Lipid Panel Test Strip that is the subject of this submission:

Similarities

The test strip is the same. There are no differences in chemical . formulation, processes or design.
. The test strip is used on the same unmodified instrument.
The intended use is the same. .

Differences

Performance: The test strips used for the new CLIA Waiver application gave better precision than those used in the original CLIA precision study. The improved precision performance is the basis of this Special 510(k). This improvement in precision was due to the scale-up of the process to manufacture larger lots of the test strips and the increase in manufacturing experience in producing this product. Once the product was manufactured on a larger scale, the precision (as measured by lot homogeneity) improved. The precision improvement supported changing the homogeneity testing acceptance criteria from 15% to 10% CV.

1. Compliance with Special Controls
  Does not apply.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows a circular logo with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES" written around the perimeter. Inside the circle is a stylized symbol consisting of three curved lines that resemble a person with outstretched arms. The logo is black and white and appears to be a seal or emblem.

Public Health Service

SEP 2 4 2002

ood and Drug Administration 2098 Gaither Road Rockville MD 20850

Mr. Margo Enright Manager of Clinical Affairs Polymer Technology Systems, Inc. 7736 Zionsville Road Indianapolis, IN 46268

Re: K022898

Trade/Device Name: Lipid Panel Test Strips Regulation Number: 21 CFR 862.1175 Regulation Name: Cholesterol (total) Test System Regulatory Class: Class I Product Code: CHH, LBR, JGY Dated: August 29, 2002 Received: September 3, 2002

Dear Mr. Enright:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmaldsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

I) Sheer fand Drago Administration - Genter for Deviace and Radiological Health

Page 1 of

K022898 510(k) Number (if known):

Device Name:

Lipid Panel Test Strips

Indications for Use:

(Division Sign-Off)
Division of Clinical Laboratory vices
510(k) Number K022898

prescription use

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Regulation Number and Section

§ 862.1175 Cholesterol (total) test system.

(a)
Identification. A cholesterol (total) test system is a device intended to measure cholesterol in plasma and serum. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.